Aprepitant for Chemotherapy-Induced Emesis — NCD 309 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 309 governing aprepitant coverage for chemotherapy-induced nausea and vomiting, with an effective date of February 14, 2026. Here's what billing teams need to know.

This CMS aprepitant coverage policy has two distinct coverage periods with different chemotherapy agent lists — and which period applies to your claim determines whether you get paid. NCD 309 in the Medicare system defines when the oral three-drug antiemetic regimen of aprepitant (Emend®), a 5HT₃ antagonist, and dexamethasone is reasonable and necessary. No specific HCPCS or CPT codes are listed in the current policy document, which creates a real documentation burden for your billing team. Get that documentation tight now — before claims start hitting.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Aprepitant for Chemotherapy-Induced Emesis
Policy Code	NCD 309
Change Type	Modified
Effective Date	2026-02-14
Impact Level	High
Specialties Affected	Oncology, Hematology/Oncology, Infusion Billing, Pharmacy Billing
Key Action	Verify the chemotherapy agent on every aprepitant claim matches the NCD 309 covered drug list for the correct coverage period before submitting

---

CMS Aprepitant Coverage Criteria and Medical Necessity Requirements 2026

The core of this CMS aprepitant coverage policy is a strict drug-list model. Coverage is not based on a diagnosis alone. It depends on which chemotherapy agent the patient is receiving.

CMS defines medical necessity for the oral three-drug regimen — oral aprepitant, an oral 5HT₃ antagonist, and oral dexamethasone — only when the patient is receiving specific anticancer agents. Miss that link in your documentation and you have a denial waiting to happen.

The policy draws a hard line between two coverage periods. The first runs from April 4, 2005, through May 28, 2013. The second runs from May 29, 2013, forward. The May 2013 expansion added 11 additional chemotherapy agents to the covered list. If you're billing for claims tied to the post-May 2013 period — which is virtually every current claim — you're working under the expanded list.

What CMS Means by "Highly Emetogenic" and "Moderately Emetogenic"

CMS doesn't let individual providers define these terms. The coverage policy anchors to an external standard: an agent qualifies as highly or moderately emetogenic if at least two of three major oncology guidelines — NCCN, ASCO, and ESMO/MASCC — classify it that way. The qualifying combinations are NCCN plus ASCO, NCCN plus ESMO/MASCC, or ASCO plus ESMO/MASCC.

This matters for your medical necessity documentation. You can't just note that the oncologist considers the regimen emetogenic. The chart should support that the chemotherapy agent itself meets this dual-guideline threshold. Your clinical documentation team needs to understand this standard.

Timing Is a Hard Requirement

CMS sets a specific administration window for the three-drug regimen. It must be given immediately before and within 48 hours after the chemotherapy agent. This isn't a soft guideline — it's a coverage condition.

If the medication administration record shows the regimen was given outside that 48-hour window, you lose the medical necessity argument. Audit your documentation workflow to confirm the timing is captured clearly and consistently.

Prior Authorization

NCD 309 does not explicitly require prior authorization at the national level. However, your Medicare Administrative Contractor may layer on local requirements. Check with your MAC before assuming prior auth isn't needed — regional variation is real here.

---

CMS Aprepitant Exclusions and Non-Covered Indications

This is where billing teams often get into trouble. The policy is direct: aprepitant cannot function as a standalone antiemetic under this coverage policy. It is not covered when used alone.

The three-drug combination is the covered unit. Remove any component — the 5HT₃ antagonist or the dexamethasone — and you no longer have a covered regimen under NCD 309. Bill accordingly.

CMS also draws a line around the chemotherapy agent list. If the patient is receiving a chemotherapy drug not on the covered list, the aprepitant regimen is not covered under this NCD — regardless of how emetogenic the treating oncologist considers it to be.

The policy does not cover aprepitant for anticipatory nausea, nausea from non-chemotherapy causes, or general symptom management outside the defined CINV context. Document the specific chemotherapy agent and the CINV indication explicitly on every claim.

---

Coverage Indications at a Glance

---

CMS Aprepitant Billing Guidelines and Action Items 2026

The practical reality of aprepitant billing under NCD 309 is that the claim lives or dies on documentation. Here's what to do now.

Copy Action Items

If your patient mix includes a lot of complex multi-drug regimens, talk to your compliance officer before the February 14, 2026, effective date kicks in fully. The combination chemotherapy scenarios — where an agent may or may not trigger coverage depending on how it's classified — can get complicated fast.

---

CPT, HCPCS, and ICD-10 Codes for Aprepitant Under NCD 309

A Note on Code Availability

The current NCD 309 policy document does not list specific CPT or HCPCS codes. This is not unusual for older NCDs that predate standardized code mapping. It does create a real aprepitant billing problem: your team has to rely on the clinical indication and drug documentation rather than a clean code match.

Work with your pharmacy billing team to confirm the correct HCPCS drug codes for aprepitant and the companion drugs (5HT₃ antagonist and dexamethasone) through your MAC or drug billing reference. Do not guess codes — submit a documentation request to your MAC if you need confirmation of the correct billing codes for this three-drug regimen under NCD 309.

What to Document in Place of Code Guidance

Since NCD 309 does not specify codes, your claim strength depends entirely on:

• The specific chemotherapy agent name, dose, and date of administration
• The names and administration dates of all three antiemetic drugs in the regimen
• The timing of the antiemetic regimen relative to chemotherapy
• The treating diagnosis (chemotherapy-induced nausea and vomiting)

Until CMS publishes updated code guidance under this modified NCD, document everything and bill what your MAC supports. If you're unsure, this is a good moment to loop in your billing consultant.

---